Literature DB >> 23452393

The incidences and mortalities of major cancers in China, 2009.

Wanqing Chen1, Rongshou Zheng, Siwei Zhang, Ping Zhao, Guanglin Li, Lingyou Wu, Jie He.   

Abstract

In 2012, the National Central Cancer Registry (NCCR) of China collected cancer registration information for the year 2009 from local cancer registries and analyzed it to describe the incidences and mortalities of cancers in China. Based on the data quality criteria from NCCR, data from 104 registries covering 85,470,522 people (57,489,009 in urban areas and 27,981,513 in rural areas) were checked and evaluated. The data from 72 registries were qualified and accepted for the cancer registry annual report in 2012. The total cancer incident cases and cancer deaths were 244,366 and 154,310, respectively. The morphologically verified cases accounted for 67.23%, and 3.14% of the incident cases only had information from death certifications. The crude incidence in the Chinese cancer registration areas was 285.91/100,000 (317.97/100,000 in males and 253.09/100,000 in females). The age-standardized rates for incidences based on the Chinese standard population (ASRIC) and the world standard population (ASRIW) were 146.87/100,000 and 191.72/100,000, respectively, with a cumulative incidence of 22.08%. The cancer mortality in the Chinese cancer registration areas was 180.54/100,000 (224.20/100,000 in males and 135.85/100,000 in females). The age-standardized rates for mortalities based on the Chinese standard population(ASRMC) and the world standard population (ASRMW) were 85.06/100,000 and 115.65/100,000, respectively, and the cumulative mortality was 12.94%. Lung cancer, gastric cancer, colorectal cancer, liver cancer, esophageal cancer, pancreatic cancer, encephaloma, lymphoma, female breast cancer, and cervical cancer were the most common cancers, accounting for 75% of all cancer cases. Lung cancer, gastric cancer, liver cancer, esophageal cancer, colorectal cancer, pancreatic cancer, breast cancer, encephaloma, leukemia, and lymphoma accounted for 80% of all cancer deaths. The cancer registration's population coverage has been increasing, and its data quality is improving. As the basis of the cancer control program, the cancer registry plays an important role in directing anticancer strategies in the medium and long term. Because cancer burdens are different in urban and rural areas in China, prevention and control efforts should be based on practical situations.

Entities:  

Mesh:

Year:  2013        PMID: 23452393      PMCID: PMC3845591          DOI: 10.5732/cjc.013.10018

Source DB:  PubMed          Journal:  Chin J Cancer        ISSN: 1944-446X


Population-based cancer registries collect the data of cancer incident cases and deaths from the covered populations to describe and monitor cancer epidemics in certain areas. The cancer registration data are used for cancer control planning, for the implementation and evaluation of cancer prevention and control efforts, and for scientific research[1]. Since 2006, when the Disease Prevention and Control Bureau, Ministry of Health of China started to publish cancer statistics annually, the National Central Cancer Registry (NCCR) of China has been responsible for collecting data from all local registries, calculating the statistical items accurately, analyzing the data of cancer incident cases and deaths from registration areas, and releasing the updated data in the Cancer Registry Annual Report[2]. The cancer statistical data have been broadly used in scientific studies, clinical trials, and decision-making for cancer prevention and control strategies.

Materials and Methods

Data source

One hundred four cancer registries from 26 provinces, including 46 urban registries and 58 rural registries, submitted cancer registration data in 2009. The coverage population of all 104 registries was 109,476,347(55,654,485 males and 53,821,862 females), accounting for 8.20% of the entire national population by the end of 2009. The total cancer incident cases were 284,470 (160,958 males and 123,512 females), and the total number of deaths was 174,879 (110,311 males and 64,568 females).

Quality control

The proportion of morphologic verification (MV%), the percentage of cancer cases identified by death certification only (DCO%), the mortality-to-incidence ratio (M/I), the percentage of uncertified cancer (UB%), and the percentage of cancer with undefined or unknown primary site (secondary) (O&U%) were used to evaluate the completeness, validity, and reliability of the cancer registration data. According to NCCR's acceptability criteria, the following standards should be reached: MV% higher than 66%, DCO% less than 15%, and M/I ratio between 0.6 and 0.8. An advantage of cancer registration data is the timely reporting of cancer. However, for the completeness, validity, and reliability of cancer statistics[3], a time gap between data updating and analysis might exist. NCCR ruled that every registry should upload the cancer registry data for 2009 before July 1, 2012, which was 30 months after the reported patients' cancer diagnoses were made.

Statistical analysis

The quality of the data was assessed based on the “Guideline for Chinese Cancer Registration” and referred to the criteria for “Cancer Incidence in Five Continents Volume IX”[4] by the International Agency for Cancer Registry (IACR) and the International Agency for Research on Cancer (IARC), respectively. When the cancer registration data met the quality criteria for completeness, comparability, and validity, they were accepted as qualified data for analysis. Crude incidence and mortality were calculated and age-standardized to the 1982 Chinese population and Segi's world population. The proportion and cumulative rate were also calculated. Database software, including MS-FoxPro, MS-Excel, SAS, and IARC issued by IARC/IACR[5], were used for data checking, evaluation, and analysis.

Results

Data pooling and quality evaluation

The data from 72 registries, including 31 from urban areas and 41 from rural areas, met the criteria for data quality and were pooled to create a national database in 2009. The population coverage of the valid database was 85,470,522 (43,231,554 males and 42,238,968 females), including 57,489,009 in urban areas (67.26%) and 27,981,513 in rural areas (32.74%). The total cancer incident cases and deaths were 244,366 and 137,462, respectively (Table 1).
Table 1.

Distribution of cancers for the total population, new cases, and deaths in each registry in 2009

Cancer RegistryCategoryTotal population
New cases
Cancer deaths
1: urban; 2: ruralBoth sexesMaleFemaleBoth sexesMaleFemaleBoth sexesMaleFemale
Beijing17,645,1863,859,5863,785,60023,33911,78411,55513,5447,9695,575
Qianxi2361,312182,138179,174767503264421313108
Shexian2394,944205,168189,7761,286802484957634323
Cixian2634,333322,621311,7121,8661,0648021,302825477
Baoding1948,612478,051470,5612,1431,1041,0391,302695607
Yangquan1683,165346,023337,1421,403807596913582331
Yangcheng2383,165192,119191,0461,272728544785504281
Chifeng11,203,006613,725589,2812,0511,1868651,325797528
Shenyang13,497,8151,722,9761,774,83910,8015,5985,2036,8914,0512,840
Dalian12,266,2241,136,7721,129,4529,3134,9034,4104,7432,9591,784
Zhuanghe2915,660461,826453,8342,3141,3101,0041,539972567
An'shan11,471,775731,916739,8594,7242,4342,2902,9581,7911,167
Benxi1955,409475,113480,2962,4591,3761,0831,6381,023615
Dandong1767,011378,794388,2172,3891,2821,1071,636974662
Donggang2640,853323,798317,0551,4328855471,141691450
Dehui2943,395479,486463,9091,9751,0629131,182687495
Yanji2440,957215,260225,697766447319464315149
Daoli District, Harbin1713,264351,071362,1931,9531,0698841,056638418
Nangang District, Harbin11,020,233508,921511,3122,3891,2461,1431,6601,005655
Shangzhi2616,046314,864301,1821,254724530653410243
Shanghai16,181,3343,084,4963,096,83825,36613,32112,04516,9339,8407,093
Jintan2545,000262,407282,5931,5619875741,242838404
Suzhou12,392,0871,183,7161,208,3718,3814,8383,5434,5042,8351,669
Haian2936,785463,612473,1732,6381,5831,0552,1081,332776
Qidong21,114,951548,805566,1463,5162,1721,3442,9281,8991,029
Haimen21,016,228501,407514,8213,6122,0771,5352,6171,709908
Lianyungang1886,862452,358434,5041,9941,1088861,306825481
Donghai21,117,858579,751538,1072,0831,2838001,506979527
Guanyun21,015,229534,502480,7271,9951,2047911,5961,068528
Chuzhou District, Huai'an11,174,877609,088565,7892,8281,7281,1001,9251,179746
Huaiyin District, Huai'an1900,027465,502434,5252,0131,3426711,399937462
Xuyi2759,450388,180371,2701,7641,0976671,077678399
Jinhu2352,292176,689175,603967572395688424264
Sheyang2965,817494,682471,1353,0521,7341,3182,2131,388825
Jianhu2805,465410,369395,0962,1501,3128381,6811,099582
Dafeng2724,147363,326360,8212,0141,1678471,597975622
Yangzhong2272,046134,758137,2881,043576467873532341
Taixing21,128,840613,199515,6412,3881,5108781,8891,264625
Hangzhou16,753,5093,403,8933,349,61622,62512,6909,93511,5927,5714,021
Jiaxing1509,367253,819255,5481,564853711912573339
Jiashan2382,475189,692192,7831,349774575958638320
Haining2653,957322,969330,9881,666915751994638356
Shangyu2771,321383462387,8592,1271,3457821,466981485
Xianju2490,070255,438234,6321,282813469998675323
Feixi2858,895449,882409,0131,9551,3466091,269920349
Maanshan1633,477323,834309,6431,7211,0386831,143770373
Tongling1433,545221,375212,1701,046644402697471226
Changle2673,717355,091318,6261,474872602828569259
Xiamen11160,135583,873576,2623,8512,2551,5962,1451,448697
Zhanggong District, Ganzhou1420,759212,159208,600904560344567366201
Linqu2817,857417,434400,4232,0431,2457981,443958485
Wenshang2762,828388,454374,3741,4058735321,130724406
Feicheng2733,501358,739374,7622,2981,3879111,488989499
Yanshi2602,266306,192296,0741,117583534748429319
Linzhou21,080,241557,392522,8492,7441,4621,2821,7011,057644
Xiping2858,002434,899423,1031,6289267021,258767491
Wuhan14,832,1742,484,6222,347,55212,5906,9785,6126,9614,5042,457
Yunmeng2524,801261,237263,564942558384767503264
Hengdong2713,458373,923339,5351,217732485728456272
Guangzhou13,968,2162,014,5801,953,63613,0627,1695,8938,1335,0933,040
Sihui2413,363211,351202,012947563384601400201
Zhongshan1,468,391732,333736,0582,9371,7831,1541,8811,289592
Liuzhou1,038,208533,050505,1582,4351,3961,0391,357862495
Fusui2444,332236,000208,332759525234529391138
Jiulongpo District, Chongqing798,618402,961395,6571,4589145441,220841379
Qingyang District, Chengdu534,701277,154257,5471,434845589880583297
Ziliujing District, Zigong357,600179,873177,727916597319462330132
Yanting2610,103316,499293,6042,3171,4818361,8501,177673
Jingtai2233,609119,953113,65639522816724415985
Liangzhou District, Wuwei1990,583524,276466,3072,8371,8869512,0241,382642
Xining1882,839439,175443,6641,492971521844585259
Xinyuan2271,944138,895133,049568330238300192108
The overall MV%, DCO%, and M/I ratio were 67.23%, 3.14%, and 0.63, respectively. They were 68.96%, 3.03%, and 0.60 in urban registries, compared with 62.91%, 3.43%, and 0.71 in rural registries.

Incidence and mortality of all cancers

Incidence

The crude incidence of all cancers in the registration areas was 285.91/100,000 (317.97/100,000 in males and 253.09/100,000 in females). The ASIRC was 146.87/100,000, and the ASIRW was 191.72/100,000. Among the patients aged 0-74 years, the cumulative incidence was 22.08%. The crude and age-standardized cancer incidences in urban areas were higher than those in rural areas. Although the crude incidence in males was much higher in urban areas than in rural areas, the age-standardized incidences were similar (Table 2).
Table 2.

The incidences of cancers (ICD10:C00-C97) registered in China in 2009

AreasGenderCancer casesCrude incidence (1/105)ASRIC (1/105)ASRIW (1/105)Cumulative rate (%)
All areasBoth sexes244,366285.91146.87191.7222.08
Male137,462317.97165.92220.3325.68
Female106,904253.09129.49166.0418.64
UrbanBoth sexes174,418303.39150.31195.7422.23
Male95,705330.19165.50219.8425.25
Female78,713276.15137.09175.0319.44
RuralBoth sexes69,948249.98139.68182.8821.76
Male41,757293.10166.94220.9426.65
Female28,191205.25113.07146.2416.83

ASRIC, age-standardized rate for the incidence based on the Chinese standard population; ASRIW, age-standardized rate for the incidence based on the world standard population; cumulative rate refers to the rate for all patients aged 0–74 years.

Mortality

The crude mortality in the cancer registration areas was 180.54/100,000 (224.20/100,000 in males and 135.85/100,000 in females). The ASMRC was 85.06/100,000, and the ASMRW was 115.65/100,000. The cumulative mortality (0–74 years) was 12.94%. Urban areas had a higher cancer mortality (181.86/100,000) than rural areas did (177.83/100,000), and both rural and urban areas had similar mortality for males. After age standardization, the mortality in rural areas was higher than that in urban areas for both males and females (Table 3).
Table 3.

Cancer mortalities in cancer registration areas in 2009

AreasGenderCancer deathsCrude mortality (1/105)ASRMC (1/105)ASRMW (1/105)Cumulative rate (%)
All areasBoth sexes154,310180.5485.06115.6512.94
Male969,27224.20110.89151.6916.94
Female573,83135.8560.5382.189.06
UrbanBoth sexes104,551181.8680.86110.5712.12
Male647,68223.45104.57143.9615.71
Female39,783139.5758.6180.008.69
RuralBoth sexes49,759177.8394.40126.7314.78
Male32,159225.73124.60168.0119.62
Female17,600128.1464.9387.089.89

ASRMC, age-standardized rate for the mortality based on the Chinese standard population; ASRMW, age-standardized rate for the mortality based on the world standard population; cumulative rate refers to the rate for all patients aged 0–74 years.

Incidence and mortality of major cancers

Cancer incidences of the 10 most common cancers

Lung cancer was the most common cancer in the cancer registration areas, followed by gastric, colorectal, liver, and esophageal cancers. The 10 most common cancers accounted for 76.39% of all new cases, including 84.14% in males and 77.57% in females. Lung cancer was the most frequently diagnosed cancer in males, followed by gastric, liver, colorectal, and esophageal cancers. Breast cancer was the most frequently diagnosed cancer in females, followed by lung, colorectal, gastric, and liver cancers (Table 4).
Table 4.

Incidences of the top 10 cancers in cancer registration areas in 2009

RankBoth sexes
Male
Female
SiteIncidence (1/105)Proportiona (%)ASRIC (1/105)SiteIncidence (1/105)Proportiona (%)ASRIC (1/105)SiteIncidence (1/105)Proportiona (%)ASRIC (1/105)
1Lung53.5718.7425.34Lung70.4022.1434.75Breast42.5516.8123.16
2Stomach36.2112.6717.85Stomach49.6115.6025.37Lung36.3414.3616.41
3Colorectum29.4410.3014.21Liver41.9913.2122.49Colorectum26.4210.4412.29
4Liver28.7110.0414.78Colorectum32.3810.1816.23Stomach22.508.8910.62
5Esophagus22.147.7410.88Esophagus30.449.5715.62Liver15.115.977.11
6Breast21.217.4211.64Prostate9.923.124.34Esophagus13.645.396.27
7Pancreas7.282.553.35Bladder9.783.084.70Cervix12.965.127.42
8Lymphoma6.682.343.75Pancreas8.242.594.01Thyroid gland10.093.996.50
9Bladder6.612.313.03Lymphoma7.712.424.46Uterus8.773.464.69
10Thyroid gland6.562.294.21Kidney7.072.223.82Ovary7.953.144.54
Top 10218.4076.39109.05267.5584.14135.81196.3277.5799.01

aProportion in all cancer incident cases. Other footnotes as in Table 2.

ASRIC, age-standardized rate for the incidence based on the Chinese standard population; ASRIW, age-standardized rate for the incidence based on the world standard population; cumulative rate refers to the rate for all patients aged 0–74 years. ASRMC, age-standardized rate for the mortality based on the Chinese standard population; ASRMW, age-standardized rate for the mortality based on the world standard population; cumulative rate refers to the rate for all patients aged 0–74 years. aProportion in all cancer incident cases. Other footnotes as in Table 2.

Cancer mortalities of the 10 most common cancers

Lung cancer was the leading cause of death in the cancer registration areas, followed by gastric, liver, esophageal, and colorectal cancers. The 10 most common cancers accounted for 84.27% of all cancer deaths. In males, lung cancer was the leading cause of death, followed by liver, gastric, esophageal, and colorectal cancers; in females, lung cancer was also the leading cause of death, followed by gastric, liver, colorectal, and breast cancers (Table 5).
Table 5.

Mortalities of the 10 most common cancers in cancer registration areas in 2009

RankBoth sexes
Male
Female
SiteMortality (1/105)Proportiona (%)ASRMC (1/105)SiteMortality (1/105)Proportiona (%)ASRMC (1/105)SiteMortality (1/105)Proportiona (%)ASRMC (1/105)
1Lung45.5725.2420.61Lung61.0027.2129.15Lung29.7721.9112.58
2Liver26.0414.4213.06Liver37.9616.9319.91Stomach16.9112.457.19
3Stomach25.8814.3311.86Stomach34.6415.4516.79Liver13.8410.196.28
4Esophagus16.779.297.75Esophagus23.2910.3911.42Colorectum12.699.345.09
5Colorectum14.237.886.15Colorectum15.737.027.28Breast10.247.544.94
6Pancreas6.613.662.98Pancreas7.453.323.59Esophagus10.117.444.22
7Breast5.132.842.52lymphoma5.002.233.43Pancreas5.754.232.41
8Leukemia4.282.372.88Leukemia4.592.052.37Gallbladder3.792.791.50
9Brain3.872.152.29Prostate4.191.871.58Brain3.552.611.99
10Lymphoma3.752.081.86Brain4.191.875.59Leukemia3.552.612.34
Top 10152.1484.2771.96198.0488.3398.11110.2081.1248.55

Footnotes as in Tables 3 and 4.

Discussion

A recent goal of the National Health Care Reform Program of China is to establish more than 300 registries covering at least one tenth of the population of all rural areas. The year 2009 is the year that the Ministry of Health in China launched the National Program of Cancer Registry. Fifty-two new cancer registries were established based on 43 existing registries supported by central finance through the registry program. According to the NCCR's data submission requirements, 95 registries were expected to submit their 2009 cancer registration data in 2012. As of June 2012, 104 cancer registries had submitted data, a great increase compared with the previous year. In 2012, a total of 222 cancer registries recorded cancer data, covering 200 million people. The number of registries is expected to increase in the coming years. NCCR will focus on improving data quality and expanding the coverage to improve the cancer surveillance system nationwide by establishing the foundations for cancer control. Footnotes as in Tables 3 and 4. To ensure the validity of accepted data, NCCR processes the data carefully according to the national criteria issued in the program protocol. The incidence, mortality, and population data must be reasonable compared with the levels for similar populations, for example, those with a similar location, socioeconomic status, and lifestyle. The indicators of completeness and validity, such as MV%, DCO%, M/I ratio, UB%, and 0&U%, were evaluated for every registry's data. Through double evaluations at the provincial and national levels, 72 registries qualified for inclusion, and 32 were considered invalid. The valid data were pooled and analyzed to create the final results for the 2009 annual report. The cancer incidence and mortality statistics for 2009 were very close to those for 2008[6]. Although the included registries were quite different from those that were included in the 2008 report, the overall cancer incidence and mortality data for the two years were reasonably stable, indicating that the pooled data were valid and could represent the cancer burden at the national level. The representativeness of the cancer registry for different groups, such as urban and rural populations and various regions, should be evaluated[7]. The cancer patterns differ considerably between urban and rural areas in China[8]. In urban areas, lung cancer, female breast cancer, and colorectal cancer are major cancers with higher incidences than in rural areas. However, cancers of the digestive system, such as esophageal cancer, gastric cancer, and liver cancer, are common in rural areas. The overall cancer incidence in urban areas is higher and mortality is lower than those in rural areas[8],[9]. This difference is the result of limited medical resources, a relatively low level of cancer diagnosis and treatment, and a lack of health education in rural areas. In urban areas, the cancer spectrum is tending toward the characteristics of developed countries. The burdens of lung cancer, colorectal cancer, and female breast cancer continue to increase. Cancer in rural areas still retains the cancer patterns of developing countries. Thus, the emphasis of cancer control should consider these differences and implement efficient strategies based on cancer surveillance results. Currently, the Ministry of Health is developing an action plan for preventing and controlling noncommunicable diseases in the twelfth 5-year plan. Cancer is a major disease seriously threatening people's health in China. The emphasis in rural areas would focus on professional training in primary care centers, health education/promotion, and early diagnosis/treatment, especially for cancers that are common in rural areas, such as esophageal, gastric, cervical, and liver cancers. In cities, behavioral interventions, such as tobacco control and healthy lifestyle promotion, should be enhanced, and high-risk groups should undergo cancer screening to achieve the goal of reducing cancer mortality within a short time.
  5 in total

Review 1.  The evolution of the population-based cancer registry.

Authors:  Donald M Parkin
Journal:  Nat Rev Cancer       Date:  2006-08       Impact factor: 60.716

2.  Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness.

Authors:  Inger Kristin Larsen; Milada Småstuen; Tom Børge Johannesen; Frøydis Langmark; Donald Maxwell Parkin; Freddie Bray; Bjørn Møller
Journal:  Eur J Cancer       Date:  2008-12-16       Impact factor: 9.162

3.  [Trend analysis of cancer mortality in China between 1989 and 2008].

Authors:  Hong-mei Zeng; Rong-shou Zheng; Si-wei Zhang; Ping Zhao; Jie He; Wan-qing Chen
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2012-07

4.  [Trend analysis and projection of cancer incidence in China between 1989 and 2008].

Authors:  Wan-qing Chen; Rong-shou Zheng; Hong-mei Zeng; Si-wei Zhang; Ping Zhao; Jie He
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2012-07

5.  Representativeness of population-based cancer registration in China--comparison of urban and rural areas.

Authors:  Guang Lin Li; Wan Qing Chen
Journal:  Asian Pac J Cancer Prev       Date:  2009 Oct-Dec
  5 in total
  91 in total

1.  Study of natural IgG antibodies against vascular endothelial growth factor receptor 1 in hepatocellular carcinoma.

Authors:  Yilai Wang; Zhaoping Yan; Yile Huang; Cailing Qiu; Xiangyun Chen; Ying Hu; Qingyong Meng; Jun Wei
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

2.  LncRNA Sox2ot overexpression serves as a poor prognostic biomarker in gastric cancer.

Authors:  Yuanyuan Zhang; Rui Yang; Jianchun Lian; Haiyan Xu
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

3.  Malignancy as a comorbidity in rheumatic diseases: a retrospective hospital-based study.

Authors:  Hai-Long Wang; Yong-Ming Zhou; Guang-Zhao Zhu; Zhu Yang; Bao-Jin Hua
Journal:  Clin Rheumatol       Date:  2017-05-16       Impact factor: 2.980

4.  BVES inhibition triggers epithelial-mesenchymal transition in human hepatocellular carcinoma.

Authors:  Ping Han; Yu Fu; Min Luo; Jiayi He; Jingmei Liu; Jiazhi Liao; Dean Tian; Wei Yan
Journal:  Dig Dis Sci       Date:  2014-01-18       Impact factor: 3.199

5.  Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population.

Authors:  Ye Chen; Dan Cao; Feng Bi; Qiu Li; Meng Qiu
Journal:  Med Oncol       Date:  2014-03-30       Impact factor: 3.064

6.  Development of a multiplex methylation specific PCR suitable for (early) detection of non-small cell lung cancer.

Authors:  Imran Nawaz; Xiaoming Qiu; Heng Wu; Yang Li; Yaguang Fan; Li-Fu Hu; Qinghua Zhou; Ingemar Ernberg
Journal:  Epigenetics       Date:  2014-06-17       Impact factor: 4.528

7.  Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy.

Authors:  Kexin Chen; Da Yang; Xiangchun Li; Baocun Sun; Fengju Song; Wenfeng Cao; Daniel J Brat; Zhibo Gao; Haixin Li; Han Liang; Yanrui Zhao; Hong Zheng; Miao Li; Jan Buckner; Scott D Patterson; Xiang Ye; Christoph Reinhard; Anahita Bhathena; Deepa Joshi; Paul S Mischel; Carlo M Croce; Yi Michael Wang; Sreekumar Raghavakaimal; Hui Li; Xin Lu; Yang Pan; Han Chang; Sujuan Ba; Longhai Luo; Webster K Cavenee; Wei Zhang; Xishan Hao
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-12       Impact factor: 11.205

8.  Long noncoding RNA NEAT1 is an unfavorable prognostic factor and regulates migration and invasion in gastric cancer.

Authors:  Jing-Wei Fu; Ying Kong; Xu Sun
Journal:  J Cancer Res Clin Oncol       Date:  2016-04-19       Impact factor: 4.553

Review 9.  Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer.

Authors:  Xiao-Yi Wang; Feng Yang; Chen Jin; De-Liang Fu
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

10.  Farnesoid X receptor antagonizes JNK signaling pathway in liver carcinogenesis by activating SOD3.

Authors:  Yan-Dong Wang; Wei-Dong Chen; Cunbao Li; Cong Guo; Yanyan Li; Hui Qi; Hailing Shen; Jing Kong; Xuecheng Long; Frank Yuan; Xichun Wang; Wendong Huang
Journal:  Mol Endocrinol       Date:  2014-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.